<DOC>
	<DOC>NCT01829061</DOC>
	<brief_summary>The Quo-Test A1C Analyzer and Reagent Test System (Quo-Test A1C System) are intended for the in-vitro quantitative determination of glycated hemoglobin in whole blood samples obtained from fingerstick or venous samples for point-of-care testing. The Quo-Test A1C System is indicated in the management and treatment of diabetes and for monitoring long term glycemic control by diabetics. It is for multiple patient use. Only auto-disabling, single use lancing devices should be used with this system.</brief_summary>
	<brief_title>Reproducibility and Method Comparison Studies of the Quo-Test™ A1C System and the Quo-Lab A1C Test and CLIA Waiver Study of the Quo-Test™ A1C System</brief_title>
	<detailed_description />
	<criteria>Aged 18 years or over Able to read English Read, understood and signed the Informed Consent Form Agrees to participate and does not withdraw\ Either healthy (without diabetes) or has Type 1 or Type 2 diabetes Exlcusion Criteria: • Declines participation or withdraws before study completion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Type I Diabetes</keyword>
	<keyword>Type II Diabetes</keyword>
	<keyword>HbA1C</keyword>
</DOC>